Skip to main content
. 2017 May 25;8(6):151. doi: 10.3390/genes8060151

Figure 1.

Figure 1

MYC, MYCN, MYCL amplifications in cancer. (a) A heatmap depicting the frequency of copy number alterations (CNAs) in MYC, MYCN, and MYCL loci across multiple cancers grouped based on tissue of origin (data mined from cbioportal.org [34,35]). The source of the genomic data is indicated in parentheses. (b) MYC amplification identified in four molecular subtypes of breast cancer [30]. (c) Long-term survival analysis of 2051 breast cancer patients (over 30 years) with MYC-amplified and non-MYC-amplified cancers (data accessed through cbioportal.org and METABRIC [29]). (d) Amplification of MYC, MYCN, and MYCL identified in two molecular subtypes of prostate cancer, castration-resistant prostate cancer (CRPC) adenocarcinoma and neuroendocrine-CRPC [36]. (e) Amplification of MYC, MYCN, and MYCL identified in four molecular subtypes of medulloblastoma [37]. (f) Correlation of MYC mRNA expression with the type of copy number alteration CNA (deletion, ploidy, gain, or amplification) in breast cancer (left, METABRIC) and prostate cancer [38] (right).